Automated Video-Assisted Smoking Treatment for People Living With HIV
NCT ID: NCT05014282
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
638 participants
INTERVENTIONAL
2021-12-15
2026-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard Treatment
Participants randomized to Standard Treatment (ST) will be provided with a 10-week supply of nicotine patches and lozenges. ST participants will be connected with their state's tobacco quitline services and will complete weekly 4-item smartphone assessments electronically for 26 weeks. The weekly assessments consist of questions on smoking status, motivation, self-efficacy, and perceived stress.
Nicotine patch
Participants will be provided with a 10-week supply of nicotine patches
Counseling
Phone counseling with the state tobacco quitline.
Nicotine lozenge
Participants will be provided with a 10-week supply of nicotine lozenges
Automated Treatment
Participants randomized to Automated Treatment (AT) will be given a 10-week supply of nicotine patches and lozenges. AT will also comprise of: 1) 12 proactive treatment videos, delivered weekly, that are tailored on smoking status, motivation, agency, and/or negative affect/stress; 2) 26 weeks of on-demand access to treatment content; 3) 26 weeks of text content
Nicotine patch
Participants will be provided with a 10-week supply of nicotine patches
Nicotine lozenge
Participants will be provided with a 10-week supply of nicotine lozenges
Smartphone-delivered automated treatment
An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nicotine patch
Participants will be provided with a 10-week supply of nicotine patches
Counseling
Phone counseling with the state tobacco quitline.
Nicotine lozenge
Participants will be provided with a 10-week supply of nicotine lozenges
Smartphone-delivered automated treatment
An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English or Spanish speaking
* Currently smoke \> 5 cigarettes/day
* Willing to make a quit attempt within 1 week of enrollment
* HIV positive
* Process a smartphone compatible with the project app
* Have a valid email address
Exclusion Criteria
* Current use of smoking cessation medications
* Enrolled in a smoking cessation study
* Household member enrolled in the study
* Failure to electronically confirm participation within 14 days of randomization via electronic link sent to participant's smartphone
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Damon J Vidrine, Dr.PH
Role: PRINCIPAL_INVESTIGATOR
Moffitt Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vidrine DJ, Bui TC, Businelle MS, Shih YT, Sutton SK, Shahani L, Hoover DS, Bowles K, Vidrine JI. Evaluating the Efficacy of Automated Smoking Treatment for People With HIV: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2021 Nov 17;10(11):e33183. doi: 10.2196/33183.
Related Links
Access external resources that provide additional context or updates about the study.
Moffitt Clinical Trial Search
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-20262
Identifier Type: -
Identifier Source: org_study_id